Press time:2016-05-17From:CR Pharm [Font:BigMediumSmall]
On May 16th, CR Pharma and the National Center for Nanoscience and Technology (NCNST) announced a strategy cooperation agreement for the establishment of a joint laboratory which focusing on nanomicelles drug development.
The NCNST of China is co-founded by Chinese Academy of Sciences (CAS) and Ministry of Education. NCNST has built a public technological platform and research base for nanoscience, which is featured with state-of-the-art equipment. NCNST has also built up a team with in-depth expertise in nanotherapy, using FDA approved materials developing with nanotechnologies to improve the bioavailability and therapeutic efficacy as well as to decrease toxicity of approved drugs by targeted delivery and controllable release.
Under the framework of the agreement, CR pharma and NCNST will focus research efforts on druggability studies of nanomaterials, conversion techniques and other key development areas, and will also conduct a wide range of cooperation in professional training, platform sharing, internship program and etc. The first project of the joint laboratory is “Nanomicells of Irinotecanhydrochloride for Injection” and is scheduled to submit the IND application by the end of this year.
